



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.usplo.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/786,549	03/07/2001	Jorg Priewe	SCH 1705	3734
23599	7590 08/11/2004		EXAM	INER
MILLEN, WHITE, ZELANO & BRANIGAN, P.C.			AZPURU, CARLOS A	
SUITE 1400	NDON BLVD.		ART UNIT	PAPER NUMBER
ARLINGTON	, VA 22201		1615	
			DATE MAILED: 08/11/2004	4

Please find below and/or attached an Office communication concerning this application or proceeding.

Advisory Action

Application No.	Applicant(s)	
09/786,549	PRIEWE ET AL.	
Examiner	Art Unit	
Carlos A. Azpuru	1615	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

THE REPLY FILED 17 November 2003 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE. Therefore, further action by the applicant is required to avoid abandonment of this application. A proper reply to a final rejection under 37 CFR 1.113 may only be either: (1) a timely filed amendment which places the application in condition for allowance; (2) a timely filed Notice of Appeal (with appeal fee); or (3) a timely filed Request for Continued Examination (RCE) in compliance with 37 CFR 1.114.

Examination (RCE) in compliance with 37 CFR 1.114.
PERIOD FOR REPLY [check either a) or b)]
a) The period for reply expires <u>5</u> months from the mailing date of the final rejection.
b) The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. I no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection. ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f).
Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).
1. A Notice of Appeal was filed on <u>05 January 2004</u> . Appellant's Brief must be filed within the period set forth in 37 CFR 1.192(a), or any extension thereof (37 CFR 1.191(d)), to avoid dismissal of the appeal.
2. The proposed amendment(s) will not be entered because:
(a) ☐ they raise new issues that would require further consideration and/or search (see NOTE below);
(b) they raise the issue of new matter (see Note below);
(c) they are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or
(d) they present additional claims without canceling a corresponding number of finally rejected claims.
NOTE:
3. Applicant's reply has overcome the following rejection(s):
4. Newly proposed or amended claim(s) would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s).
5. ☐ The a) ☐ affidavit, b) ☐ exhibit, or c) ☐ request for reconsideration has been considered but does NOT place the application in condition for allowance because: <u>See Continuation Sheet</u> .
6. The affidavit or exhibit will NOT be considered because it is not directed SOLELY to issues which were newly raised by the Examiner in the final rejection.
7. For purposes of Appeal, the proposed amendment(s) a) will not be entered or b) will be entered and an explanation of how the new or amended claims would be rejected is provided below or appended.
The status of the claim(s) is (or will be) as follows:
Claim(s) allowed:
Claim(s) objected to:
Claim(s) rejected: <u>1,2,4-14 and 16-19</u> .
Claim(s) withdrawn from consideration: 20 and 21.
8. The drawing correction filed on is a) approved or b) disapproved by the Examiner.
9. Note the attached Information Disclosure Statement(s)(PTO-1449) Paper No(s).
10. Other:
CARLOS A AZPURU PRIMARY EXAMINER

U.S. Patent and Trademark Office PTOL-303 (Rev. 11-03) **GROUP 1500**

Continuation of 5. does NOT place the application in condition for allowance because: In reviewing the references, it is not agreed that selection of the claimed polymers would have been an undue burden on the ordinary practitioner. The references teach an equivalence between the claimed polymers, and teach that they may additionally be used in a variety of medical devices. Simply because the Goldman reference includes a broad teaching, does not make it an improper reference for use in a rejection under 35 USC 103. Further, unlike the facts of In re Baird, the primary reference here does not teach away from the claimed polymers, instead it teaches that one of the polymers claimed may be used as a coating for stents. The secondary reference was used only as a teaching of equivalence between the claimed polymers. This is differentiated from the facts of In re Baird, where a different borate compound was taught by the primary reference than that of the claims, and the secondary reference was used to show the equivalence between the borate of the reference,m and the one which was claimed. The are no unusual and/or unexpected results which would rebut prima facie obviousness. The rejections under 35 USC 103 are hereby maintained.